‘JEB’ - a carboplatin based regimen for malignant germ cell tumours in children

Pinkerton, CR, Broadbent, V, Horwich, A, Levitt, J, McElwain, TJ, Meller, ST, Mott, M, Oakhill, A and Pritchard, J (1990) ‘JEB’ - a carboplatin based regimen for malignant germ cell tumours in children. British Journal of Cancer, 62 2: 257-262. doi:10.1038/bjc.1990.272

Author Pinkerton, CR
Broadbent, V
Horwich, A
Levitt, J
McElwain, TJ
Meller, ST
Mott, M
Oakhill, A
Pritchard, J
Title ‘JEB’ - a carboplatin based regimen for malignant germ cell tumours in children
Journal name British Journal of Cancer   Check publisher's open access policy
ISSN 1532-1827
Publication date 1990-01-01
Year available 1990
Sub-type Article (original research)
DOI 10.1038/bjc.1990.272
Open Access Status Not yet assessed
Volume 62
Issue 2
Start page 257
End page 262
Total pages 6
Language eng
Subject 1306 Cancer Research
2730 Oncology
Abstract Between February 1986 and July 1988 a total of 21 children aged 1 to 16 years with malignant germ cell tumours (MGCT), 18 with either metastatic disease or unresectable primary tumour, received the JEB regimen - carboplatin dosage calculated from the EDTA glomerular filtration rate (approximately 600 mg m−2), etoposide 120 mg m-2 daily x 3, and bleomycin 15 mg m-2 weekly. Primary sites were: testis (6), ovary (8), sacrococcyx (4), pineal gland (2) and vagina (1). AFP levels were elevated in 19, β-HCG in 8. Complete marker response was achieved in 19 out of 19 evaluable patients and complete remission of measurable tumour in 16 out of 19, 12 with chemotherapy alone and 4 with the addition of surgery. A reduction in glomerular filtration rate greater than 10% occurred in 3 of 12 evaluable patients; in none greater than 20%. Sequential audiography was normal in 11 out of 12 evaluated. The regimen was myelosuppressive with WHO grade III or IV myelosuppression occurring in 12 patients. Three patients have relapsed; one with a pineal germinoma who relapsed in the abdomen six months after diagnosis, and two with sacrococcygeal teratomas and lung metastases. Two of these remain in second complete remission after further treatment. There was one death from probable bleomycin pulmonary toxicity. We conclude that this regimen is simple to administer and, apart from myelosuppression, it is well tolerated. It appears to have comparable efficacy to cisplatin-based regimens but with much less nephrotoxicity and ototoxicity and avoids the use of alkylating agents and anthracyclines.
Keyword Oncology
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Article (original research)
Collection: ResearcherID Downloads - Archived
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 44 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 51 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sat, 09 Jul 2016, 04:24:49 EST by System User